Xilio Therapeutics Inc. (XLO)
0.68
-0.04 (-6.13%)
At close: Apr 01, 2025, 3:59 PM
0.67
-1.86%
Pre-market: Apr 02, 2025, 04:35 AM EDT
-6.13% (1D)
| Bid | 0.65 |
| Market Cap | 35.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -1.12 |
| Analyst | Buy |
| Ask | 0.76 |
| Volume | 251,995 |
| Avg. Volume (20D) | 3,945,816 |
| Open | 0.73 |
| Previous Close | 0.72 |
| Day's Range | 0.68 - 0.73 |
| 52-Week Range | 0.63 - 1.70 |
| Beta | -0.34 |
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2021
Employees 64
Stock Exchange NASDAQ
Ticker Symbol XLO
Website https://www.xiliotx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for XLO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 486.85% from the latest price.
Stock Forecasts3 weeks ago
-6.2%
Xilio Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
1 month ago
+125.27%
Xilio Therapeutics shares are trading higher after the company announced an option-to-license collaboration agreement with AbbVie to develop novel tumor-activated antibody-based immunotherapies.
